<p>2025 年 12 月 02 日- 上午 08:50</p>
<p><strong>任命進一步增強了臨牀和轉化深度，Ernexa 將其一流的 iMSC 細胞治療平台推進至首次人體試驗</strong></p>
<p>馬薩諸塞州劍橋，2025 年 12 月 02 日（GLOBE NEWSWIRE）-- Ernexa Therapeutics（納斯達克：ERNA），一家開發用於治療晚期癌症和自身免疫疾病的新型細胞療法的行業創新者，今天宣佈任命 Ira S. Winer 博士，醫學博士，哲學博士，FACOG，加入其科學和醫學顧問委員會。</p>
<p>Winer 博士是一位全國知名的婦科腫瘤學家和轉化科學家。他在女性腫瘤學、免疫治療和早期臨牀開發方面的專業知識進一步增強了 Ernexa 的能力，推動其專有的誘導性間充質幹細胞（iMSC）平台及其主導項目 ERNA-101 朝着關鍵里程碑邁進，包括首次人體試驗。</p>
<p>“我們很高興歡迎 Winer 博士加入我們的顧問委員會，” Ernexa Therapeutics 的總裁兼首席執行官 Sanjeev Luther 表示。“他在女性腫瘤學方面深厚的臨牀和轉化經驗直接支持了我們推進晚期癌症和自身免疫疾病治療的使命。當我們在卵巢癌方面推進 ERNA-101 並將我們的管道擴展到炎症和自身免疫指徵時，Winer 博士的戰略指導將幫助我們將創新轉化為有意義的臨牀結果。”</p>
<p>Winer 博士補充道：“我很榮幸在如此關鍵的時刻加入 Ernexa Therapeutics 的顧問委員會。Ernexa 專注於將誘導性多能幹細胞（iPSCs）工程化為同種異體 iMSCs 作為現成療法，體現了科學創新和對患者的深切承諾。我期待着貢獻我的轉化和臨牀科學經驗，幫助指導 Ernexa 從有前景的創新走向有意義的患者結果。”</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png"/></p>
<p>Winer 博士在韋恩州立大學醫學院腫瘤學系擔任教授（臨牀教育者），並在巴巴拉·安·卡曼諾斯癌症研究所擔任傑出的婦科腫瘤學家和外科腫瘤學家。在卡曼諾斯，Winer 博士因其外科技能和在早期臨牀試驗中的領導能力而廣受認可，為患者提供卵巢癌、子宮內膜癌、宮頸癌、輸卵管癌和外陰癌的前沿治療。</p>
<p>除了他的臨牀實踐外，他還擁有細胞和分子生物學的博士學位，使他的婦科癌症研究基於科學創新和轉化研究。Winer 博士廣泛發表論文，並積極參與專業學會，他的工作重點是卵巢癌、子宮癌、宮頸癌和外陰癌，特別強調免疫治療、分子靶向治療以及連接實驗室科學與患者護理的轉化研究。</p>
<p><strong>關於 Ernexa Therapeutics</strong></p>
<p>Ernexa Therapeutics（納斯達克：ERNA）正在開發用於治療晚期癌症和自身免疫疾病的創新細胞療法。Ernexa 的核心技術專注於將誘導性多能幹細胞（iPSCs）工程化並轉化為誘導性間充質幹細胞（iMSCs）。Ernexa 的同種異體合成 iMSCs 提供了一種可擴展的現成治療解決方案，無需患者特定的細胞採集。</p>
<p>ERNA-101 是該公司的主導細胞治療產品，旨在激活和調節免疫系統對癌細胞的識別和攻擊。ERNA-201 是一個旨在針對炎症和治療自身免疫疾病的細胞治療產品。該公司的初步重點是開發 ERNA-101 用於治療卵巢癌。</p>
<p>欲瞭解更多信息，請訪問 www.ernexatx.com。</p>
<p><strong>媒體聯繫</strong></p>
<p>Sharon Golubchik</p>
<p>RAYNZ</p>
<p>sharon@raynzhealth.com</p>
<p><strong>投資者聯繫</strong></p>
<p>Jenene Thomas</p>
<p>JTC Team, LLC</p>
<p>(908) 824-0775</p>
<p>ENRA@jtcir.com</p>
<p>與此公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/de652864-7d39-4b89-873f-72a4b65d76be 獲取</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5EZzFNaU0zTXpBd05UQXdJekl5TVRBeU9EQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5EZzFNaU0zTXpBd05UQXdJekl5TVRBeU9EQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png"/></p>

ERNA

<p>Ernexa Therapeutics 已任命領先的腫瘤學家 Ira S. Winer 博士為其科學與醫學顧問委員會成員。此舉旨在增強 Ernexa 在推進其 iMSC 細胞治療平台進入首次人體試驗中的臨牀和轉化能力。Winer 博士在女性腫瘤學和免疫治療方面的專業知識將支持 Ernexa 開發針對晚期癌症和自身免疫疾病的治療，特別是聚焦於卵巢癌</p>

<p>12/02/2025 - 08:50 AM</p>
<div class="lb-trans"><p>2025 年 12 月 02 日- 上午 08:50</p>
</div><p><strong>Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials</strong></p>
<div class="lb-trans"><p><strong>任命進一步增強了臨牀和轉化深度，Ernexa 將其一流的 iMSC 細胞治療平台推進至首次人體試驗</strong></p>
</div><p>CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board.</p>
<div class="lb-trans"><p>馬薩諸塞州劍橋，2025 年 12 月 02 日（GLOBE NEWSWIRE）-- Ernexa Therapeutics（納斯達克：ERNA），一家開發用於治療晚期癌症和自身免疫疾病的新型細胞療法的行業創新者，今天宣佈任命 Ira S. Winer 博士，醫學博士，哲學博士，FACOG，加入其科學和醫學顧問委員會。</p>
</div><p>Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women’s oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa’s capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human trials.</p>
<div class="lb-trans"><p>Winer 博士是一位全國知名的婦科腫瘤學家和轉化科學家。他在女性腫瘤學、免疫治療和早期臨牀開發方面的專業知識進一步增強了 Ernexa 的能力，推動其專有的誘導性間充質幹細胞（iMSC）平台及其主導項目 ERNA-101 朝着關鍵里程碑邁進，包括首次人體試驗。</p>
</div><p>“We are delighted to welcome Dr. Winer to our Advisory Board,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “His deep clinical and translational experience in women’s oncology directly supports our mission to advance treatments for advanced cancer and autoimmune disease. As we move ERNA-101 forward in ovarian cancer and expand our pipeline into inflammatory and autoimmune indications, Dr. Winer’s strategic guidance will help us translate innovation into meaningful clinical outcomes.”</p>
<div class="lb-trans"><p>“我們很高興歡迎 Winer 博士加入我們的顧問委員會，” Ernexa Therapeutics 的總裁兼首席執行官 Sanjeev Luther 表示。“他在女性腫瘤學方面深厚的臨牀和轉化經驗直接支持了我們推進晚期癌症和自身免疫疾病治療的使命。當我們在卵巢癌方面推進 ERNA-101 並將我們的管道擴展到炎症和自身免疫指徵時，Winer 博士的戰略指導將幫助我們將創新轉化為有意義的臨牀結果。”</p>
</div><p>Dr. Winer added, “I am honored to join the Advisory Board of Ernexa Therapeutics at such a pivotal moment. Ernexa’s focus on engineering induced pluripotent stem cells (iPSCs) into allogeneic iMSCs as off-the-shelf therapies reflects both scientific innovation and a deep commitment to patients. I look forward to contributing my experience in translational and clinical science to help guide Ernexa’s path from promising innovation to meaningful patient outcomes.”</p>
<div class="lb-trans"><p>Winer 博士補充道：“我很榮幸在如此關鍵的時刻加入 Ernexa Therapeutics 的顧問委員會。Ernexa 專注於將誘導性多能幹細胞（iPSCs）工程化為同種異體 iMSCs 作為現成療法，體現了科學創新和對患者的深切承諾。我期待着貢獻我的轉化和臨牀科學經驗，幫助指導 Ernexa 從有前景的創新走向有意義的患者結果。”</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png"/></p>
<p>Dr. Winer serves as a Professor (Clinician Educator) in the Department of Oncology at Wayne State University School of Medicine, and as a distinguished gynecologic oncologist and surgical oncologist at the Barbara Ann Karmanos Cancer Institute. At Karmanos, Dr. Winer is widely recognized for his surgical skill and leadership in early-phase clinical trials, offering patients access to cutting-edge therapies in ovarian, endometrial, cervical, fallopian tube, and vulvar cancers.</p>
<div class="lb-trans"><p>Winer 博士在韋恩州立大學醫學院腫瘤學系擔任教授（臨牀教育者），並在巴巴拉·安·卡曼諾斯癌症研究所擔任傑出的婦科腫瘤學家和外科腫瘤學家。在卡曼諾斯，Winer 博士因其外科技能和在早期臨牀試驗中的領導能力而廣受認可，為患者提供卵巢癌、子宮內膜癌、宮頸癌、輸卵管癌和外陰癌的前沿治療。</p>
</div><p>In addition to his clinical practice, he holds a Ph.D. in cellular and molecular biology, grounding his approach to gynecologic cancers in scientific innovation and translational research. Widely published and an active member of professional societies, Dr. Winer’s work focuses on ovarian, uterine, cervical, and vulvar cancers, with a particular emphasis on immunotherapy, molecularly targeted treatments, and translational research that bridges laboratory science and patient care.</p>
<div class="lb-trans"><p>除了他的臨牀實踐外，他還擁有細胞和分子生物學的博士學位，使他的婦科癌症研究基於科學創新和轉化研究。Winer 博士廣泛發表論文，並積極參與專業學會，他的工作重點是卵巢癌、子宮癌、宮頸癌和外陰癌，特別強調免疫治療、分子靶向治療以及連接實驗室科學與患者護理的轉化研究。</p>
</div><p><strong>About Ernexa Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Ernexa Therapeutics</strong></p>
</div><p>Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.</p>
<div class="lb-trans"><p>Ernexa Therapeutics（納斯達克：ERNA）正在開發用於治療晚期癌症和自身免疫疾病的創新細胞療法。Ernexa 的核心技術專注於將誘導性多能幹細胞（iPSCs）工程化並轉化為誘導性間充質幹細胞（iMSCs）。Ernexa 的同種異體合成 iMSCs 提供了一種可擴展的現成治療解決方案，無需患者特定的細胞採集。</p>
</div><p>ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.</p>
<div class="lb-trans"><p>ERNA-101 是該公司的主導細胞治療產品，旨在激活和調節免疫系統對癌細胞的識別和攻擊。ERNA-201 是一個旨在針對炎症和治療自身免疫疾病的細胞治療產品。該公司的初步重點是開發 ERNA-101 用於治療卵巢癌。</p>
</div><p>For more information, visit www.ernexatx.com.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.ernexatx.com。</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫</strong></p>
</div><p>Sharon Golubchik</p>
<div class="lb-trans"><p>Sharon Golubchik</p>
</div><p>RAYNZ</p>
<div class="lb-trans"><p>RAYNZ</p>
</div><p>sharon@raynzhealth.com</p>
<div class="lb-trans"><p>sharon@raynzhealth.com</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫</strong></p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>(908) 824-0775</p>
<div class="lb-trans"><p>(908) 824-0775</p>
</div><p>ENRA@jtcir.com</p>
<div class="lb-trans"><p>ENRA@jtcir.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de652864-7d39-4b89-873f-72a4b65d76be</p>
<div class="lb-trans"><p>與此公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/de652864-7d39-4b89-873f-72a4b65d76be 獲取</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5EZzFNaU0zTXpBd05UQXdJekl5TVRBeU9EQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5NDg1MiM3MzAwNTAwIzIyMTAyODA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png"/></p>

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG | ERNA Stock News

Ernexa Therapeutics 通過任命著名腫瘤學家 Ira S. Winer 博士（醫學博士，FACOG），加強了其科學和醫學諮詢委員會 | ERNA 股票新聞